Protocol Ledger

NCT05708235 · Phase II · ACTIVE NOT RECRUITING

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Interventional Phase II clinical trial protocol NCT05708235 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-01 Enrollment: 976 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05708235
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)976 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05708235
Protocol FieldVerified Registry Value
NCT IdentifierNCT05708235
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment976 participants (ESTIMATED)
Registered Start Date2024-04-01
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI